Global semiconductor developer BluGlass Limited has secured a USD 1.28 million (AUD 1.93 million) payment from a European wafer developer.
This payment pertains to the acquisition of intellectual property (IP) rights related to gallium nitride (GaN) growth techniques on the customer’s specialty wafers, the company said in an ASX announcement.
The specialist IP was developed by BluGlass under a paid contract development program that began in January 2022.
With this agreement, BluGlass will continue to provide contract foundry services for the customer, focusing on developing GaN applications on specialty wafers. Increased volumes are expected as the collaboration progresses.
“Solving complex customer challenges is a key tenet of BluGlass’ value proposition, enabling us to build long-term partnerships,” said BluGlass CEO Jim Haden.
The exclusive IP transfer, effective upon payment, is specific to MOCVD (Metal-Organic Chemical Vapor Deposition) of GaN on the customer’s unique wafer technology.
This agreement does not include any transfer of BluGlass’ RPCVD (Remote Plasma Chemical Vapor Deposition), device, or laser intellectual property.
Jim Haden emphasised the significance of this transaction, stating, “The Company’s foundry services leverage our more than a decade of GaN epitaxy expertise to assist in developing next-generation applications.”
He continued, “We’re continuing to support this foundry customer under a paid development contract, with the IP acquisition enabling us to expand our collaboration into a commercial manufacturing contract as the customer’s opportunity matures.”
Importantly, the transfer of IP is restricted to the use of MOCVD GaN growth on the customer’s specialty wafers.
“BluGlass has retained all other IP rights,” Haden clarified, highlighting the company’s strategic approach in safeguarding its broader technological assets while fostering deeper industry collaborations.
